Estrella Immunopharma, Inc. Quarterly Debt-to-equity in % from Q2 2022 to Q3 2024

Taxonomy & unit: ratio: %
Description: Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary: Estrella Immunopharma, Inc. quarterly Debt-to-equity history and growth rate from Q2 2022 to Q3 2024.
Estrella Immunopharma, Inc. Debt-to-equity for the quarter ending September 30, 2024 was 16.4 %.

Debt-to-equity, Quarterly (%)

Debt-to-equity, YoY Quarterly Growth (%)

Period	Value	YoY Chg	Change %	Date
Q3 2024	16.4	+205		Sep 30, 2024
Q2 2024	56.5	+113		Jun 30, 2024
Q1 2024	174	+220		Mar 31, 2024
Q4 2023	-1.74K	-1.67K	-2538%	Dec 31, 2023
Q3 2023	-188	-85.6	-83.4%	Sep 30, 2023
Q2 2023	-56.1	+105	+65.2%	Jun 30, 2023
Q1 2023	-46.1			Mar 31, 2023
Q4 2022	-65.9			Dec 31, 2022
Q3 2022	-103			Sep 30, 2022
Q2 2022	-161			Jun 30, 2022

* An asterisk sign (*) next to the value indicates that the value is likely invalid.